NA
ALNA

Neuburgh Advisers’s Allena Pharmaceuticals ALNA Stock Holding History

Neuburgh Advisers’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-986
Closed -$4K – 943
2019
Q2 		$4K Hold
986
– – ﹤0.01% 911
2019
Q1 		$7K Sell
986
-34
-3% -$247 ﹤0.01% 903
2018
Q4 		$6K Buy
+1,020
New +$8.79K ﹤0.01% 888

Other funds holding ALNA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Neuburgh Advisers's ALNA Position: Q3 2019 in Review

Neuburgh Advisers sold out of Allena Pharmaceuticals (ALNA) in Q3 2019, closing a stake of 986 shares — an estimated $4K sold.

Neuburgh Advisers first reported a position in ALNA in Q4 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2019. 35 funds tracked by Wall St. Rank hold ALNA as of Q3 2019.

  • Neuburgh Advisers reported no remaining Allena Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 986 Allena Pharmaceuticals shares in Q3 2019, an estimated $4K.
  • Neuburgh Advisers first reported a position in Allena Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Neuburgh Advisers's Allena Pharmaceuticals position peaked at $7K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.